{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:15:48Z","timestamp":1774530948762,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T00:00:00Z","timestamp":1475107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ipilimumab produces durable responses in some metastatic melanoma patients. Neutrophil, platelet, and eosinophil to lymphocyte ratios (<jats:styled-content style=\"fixed-case\">NLR<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> PLR<\/jats:styled-content>, and <jats:styled-content style=\"fixed-case\">ELR<\/jats:styled-content>) may be associated with the immune response in cancer thereby acting as biomarkers of toxicity and efficacy in ipilimumab\u2010treated patients. Data were collected on clinical characteristics and lactate dehydrogenase (LDH), NLR, PLR, and ELR at baseline, post cycle 2 and at the end of treatment for 183 patients treated with ipilimumab between 2008 and 2015 at the Princess Margaret Cancer Centre. Associations between clinical characteristics, <jats:styled-content style=\"fixed-case\">LDH<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> NLR<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> PLR<\/jats:styled-content>, and <jats:styled-content style=\"fixed-case\">ELR<\/jats:styled-content> with toxicity or survival outcomes of progression\u2010free (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) and overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) were assessed using univariable and multivariable analysis. Prognostic models of outcome at each time point were determined. Of the 183 patients included, the median age was 58, 85% had M1c disease, 58% were performance status 1, and 64% received ipilimumab as second line therapy. Median follow up was 7.5\u00a0months (range: 0.3\u201349.5), median <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> was 2.8\u00a0months (95% confidence intervals (CI): 2.8\u20133.2), and median <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> was 9.6\u00a0months (95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 7.9\u201313.2). Prognostic factors for <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> by multivariable analysis were <jats:styled-content style=\"fixed-case\">LDH<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">NLR<\/jats:styled-content> at all\u2010time points. Prognostic models using <jats:styled-content style=\"fixed-case\">LDH<\/jats:styled-content> (\u00d7\u00a02 upper limit of normal) and <jats:styled-content style=\"fixed-case\">NLR<\/jats:styled-content> 4) differentiated patients into high, moderate, and low risk of death prior to or on ipilimumab treatment (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.0001 for each model). No factors were associated with toxicity. Prognostic models based on <jats:styled-content style=\"fixed-case\">NLR<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">LDH<\/jats:styled-content> values at baseline and on treatment differentiate patients into good, intermediate, and poor prognostic groups and may be relevant in patient management.<\/jats:p>","DOI":"10.1002\/cam4.878","type":"journal-article","created":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T10:26:57Z","timestamp":1475144817000},"page":"2792-2799","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["The full blood count as a biomarker of outcome and toxicity in ipilimumab\u2010treated cutaneous metastatic melanoma"],"prefix":"10.1002","volume":"5","author":[{"given":"Leila","family":"Khoja","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre 610 University Avenue. M5G2M9  Toronto Canada"},{"name":"Astrazeneca plc Melbourn Science Park  DaVinci Building Melbourn United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eshetu G.","family":"Atenafu","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre 610 University Avenue. M5G2M9  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnoud","family":"Templeton","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre 610 University Avenue. M5G2M9  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Qye","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre 610 University Avenue. M5G2M9  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Anne","family":"Chappell","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre 610 University Avenue. M5G2M9  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Saibil","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre 610 University Avenue. M5G2M9  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hogg","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre 610 University Avenue. M5G2M9  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus O.","family":"Butler","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre 610 University Avenue. M5G2M9  Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony M.","family":"Joshua","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre 610 University Avenue. M5G2M9  Toronto Canada"},{"name":"Kinghorn Cancer Centre St Vincents Hospital  Sydney Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,9,29]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2736"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60958-2"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305133"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/857519"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406498"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13988"},{"key":"e_1_2_6_12_1","first-page":"449","article-title":"Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma","volume":"63","author":"Kelderman S.","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1418-6"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt027"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24951"},{"key":"e_1_2_6_16_1","doi-asserted-by":"crossref","unstructured":"Schindler K. K.Harmankaya D.Kuk J.Mangana O.Michielin C.Hoeller et\u00a0al. 2014.Correlation of absolute and relative eosinophil counts with immune\u2010related adverse events in melanoma patients treated with ipilimumab. ASCO Meeting Abstracts 32(15_suppl.):9096.","DOI":"10.1200\/jco.2014.32.15_suppl.9096"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14155"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.180"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.06.130"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/tri.12229"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju124"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-0146"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605462"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.189"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04046-0"},{"key":"e_1_2_6_26_1","article-title":"Increases in absolute lymphocytes and circulating CD4 + and CD8 + T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab","author":"Martens A.","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2412"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2834"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.023"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2014.885984"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1630"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt587"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.878","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.878","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.878","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T18:09:51Z","timestamp":1696615791000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,29]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1002\/cam4.878"],"URL":"https:\/\/doi.org\/10.1002\/cam4.878","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,29]]},"assertion":[{"value":"2016-05-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}